Monte Rosa Therapeutics
GLUE
10.17
+0.30
+3.04%
Monte Rosa Therapeutics
US · GLUE
#3350 by market cap
Listed 2021
10.17
+0.30
+3.04%
Live - 5344 symbols - heartbeat 283s ago
· 2026-10-08 09:06
Pre-market
10.02
-1.51%
After-hours
10.00
-1.67%
Overnight
10.14
-0.29%
- Market cap
- 867.64M
- P/E (TTM)i
- -5.81
- P/Bi
- 1.78
- EPSi
- -0.46
- Div yieldi
- 0.00%
- 52W posi
- 7%
Reader sentiment
Are you bullish or bearish on GLUE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.68, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +63.54% YoY
Margins
- Operating margin
- -43.83%
- Net margin
- -31.23%
Key ratios & quality
- Altman Z-Scorei
- 1.68
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | 75.62M | 123.67M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 644.00K | 4.01M | 15.73M | 27.32M | 32.04M | 35.17M | 36.38M |
| Research & development | 7.35M | 24.01M | 57.16M | 85.06M | 111.27M | 121.56M | 141.50M |
| Operating profit | -7.99M | -28.01M | -72.88M | -112.38M | -143.31M | -81.11M | -54.21M |
| Pretax profit | -7.74M | -35.88M | -73.96M | -108.50M | -135.01M | -70.13M | -39.72M |
| Tax | -- | -- | -- | 0 | 338.00K | 2.57M | -1.10M |
| Net profit | -7.74M | -35.88M | -73.96M | -108.50M | -135.35M | -72.70M | -38.63M |
| Basic EPS | -1 | -2 | -3 | -2 | -3 | -1 | 0 |
| Diluted EPS | -0.69 | -1.65 | -2.96 | -2.30 | -2.63 | -0.98 | -0.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 84.93M | 23.19M | 12.77M | 2.78M | 4.21M | 8.97M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.70M | 8.10M | 9.07M | 10.52M | 10.18M | 10.13M |
| Research & development | 32.19M | 30.65M | 36.68M | 41.98M | 44.07M | 47.96M |
| Operating profit | 44.04M | -15.55M | -32.98M | -49.72M | -50.03M | -49.13M |
| Pretax profit | 47.71M | -11.10M | -30.26M | -46.08M | -44.45M | -43.19M |
| Tax | 822.00K | 1.20M | -3.18M | 59.00K | 52.00K | 208.00K |
| Net profit | 46.89M | -12.30M | -27.08M | -46.14M | -44.50M | -43.40M |
| Basic EPS | 1 | 0 | 0 | -1 | 0 | 0 |
| Diluted EPS | 0.57 | -0.15 | -0.33 | -0.70 | -0.45 | -0.43 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 9.76M | 43.59M | 348.67M | 275.89M | 236.21M | 377.44M | 393.19M |
| Cash & ST investments | 6.00M | 41.70M | 346.07M | 262.83M | 232.41M | 372.15M | 377.10M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 11.09M | 49.38M | 366.33M | 342.39M | 303.76M | 438.73M | 448.66M |
| Total current liabilities | 4.29M | 29.28M | 16.64M | 25.57M | 46.59M | 156.95M | 64.21M |
| Short-term debt | 750.00K | -- | -- | 3.13M | 3.16M | 3.71M | 4.40M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 23,242,000.00 | 98,106,000.00 | 18,814,000.00 | 70,976,000.00 | 124,505,000.00 | 215,796,000.00 | 215,603,000.00 |
| Total equity | -12.15M | -48.73M | 347.52M | 271.41M | 179.25M | 222.94M | 233.06M |
| Retained earnings | -12.20M | -48.08M | -122.04M | -230.54M | -365.89M | -438.59M | -477.21M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 332.28M | 299.47M | 401.82M | 393.19M | 677.55M | 631.41M |
| Cash & ST investments | 326.07M | 290.59M | 391.26M | 377.10M | 666.22M | 621.10M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 393.20M | 359.59M | 459.84M | 448.66M | 736.43M | 691.16M |
| Total current liabilities | 59.22M | 41.85M | 61.44M | 64.21M | 71.04M | 59.66M |
| Short-term debt | 3.87M | 4.09M | 4.24M | 4.40M | 4.48M | 4.63M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 118,039,000.00 | 91,506,000.00 | 214,004,000.00 | 215,603,000.00 | 214,512,000.00 | 203,880,000.00 |
| Total equity | 275.16M | 268.08M | 245.84M | 233.06M | 521.92M | 487.28M |
| Retained earnings | -391.70M | -404.00M | -431.08M | -477.21M | -521.72M | -565.11M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -6.17M | -23.05M | -59.36M | -92.47M | -43.80M | 42.00M | -22.80M |
| Depreciation & amortization | 72.00K | 537.00K | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| Free cash flow | -7.56M | -26.44M | -69.10M | -105.38M | -62.84M | 38.01M | -27.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 237.75M | 20.06M | -116.00K | 303.00K | 23.89M |
| Ending cash balance | 9.25M | 42.86M | 351.41M | 60.19M | 132.68M | 229.12M | 134.84M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -45.49M | -34.72M | 100.43M | -43.01M | -37.37M | -44.11M |
| Depreciation & amortization | 2.05M | 2.13M | 2.10M | 2.09M | 2.03M | 1.91M |
| Free cash flow | -47.08M | -36.42M | 99.78M | -43.78M | -39.24M | -48.84M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 23.89M | 324.30M | 0 |
| Ending cash balance | 83.41M | 74.38M | 213.29M | 134.84M | 164.81M | 95.04M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -49.51 | -35.06 | -60.07 | -36.15 | -16.94 |
| ROA %i | -69.77 | -118.66 | -35.58 | -30.62 | -41.90 | -19.58 | -8.71 |
| ROIC %i | -- | -- | -49.54 | -31.49 | -53.22 | -33.02 | -19.04 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -39.55 |
| EBIT margin %i | -- | -- | -- | -- | -- | -107.26 | -43.83 |
| FCF / sales %i | -- | -- | -- | -- | -- | 50.26 | -- |
| Current ratioi | 2.27 | 1.49 | 20.96 | 10.79 | 5.07 | 2.40 | 6.12 |
| Quick ratioi | 1.40 | 1.42 | 20.80 | 10.58 | 5.00 | 2.37 | 6.05 |
| Debt / assetsi | 6.76 | -- | 0.00 | 13.73 | 15.16 | 9.74 | 8.74 |
| LT debt / equityi | -- | -- | -- | 16.17 | 23.92 | 17.49 | 14.93 |
| Interest coveragei | -7,739.00 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 2.88 | 9.81 | 9.28 | -16.94 | -32.62 | -42.66 |
| ROA %i | 1.86 | 6.87 | 5.41 | -8.71 | -23.02 | -30.67 |
| ROIC %i | -0.53 | 4.83 | 3.60 | -19.04 | -33.01 | -42.84 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1.33 | 8.40 | 4.69 | -43.83 | -345.21 | -633.04 |
| FCF / sales %i | 19.11 | 13.40 | 79.89 | -- | -- | -- |
| Current ratioi | 5.61 | 7.16 | 6.54 | 6.12 | 9.54 | 10.58 |
| Quick ratioi | 5.53 | 7.00 | 6.45 | 6.05 | 9.44 | 10.49 |
| Debt / assetsi | 10.65 | 11.44 | 8.74 | 8.74 | 5.30 | 5.50 |
| LT debt / equityi | 13.81 | 13.82 | 14.61 | 14.93 | 6.63 | 6.85 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)100.00%
Quote time 2026-10-08 09:06:36 · For reference only, not investment advice and not tailored to your situation.